Table S1. NIV-associated data over the course of the study.
| Variables | Groups | 15 min | 1 h | 3 h | 6 h | 12 h | 24 h | 36 h | 48 h | 60 h | 72 h |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MV settings | |||||||||||
| Support pressure, cmH2O | Remifentanil | 10 (10, 12) | 12 (10, 12) | 12 (10, 12) | 12 (10, 12) | 12 (10, 12) | 12 (10, 12) | 12 (10, 12) | 12 (10, 12) | 12 (10, 12) | 12 (11, 14) |
| Dexmedetomidine | 12 (10, 12) | 12 (10, 12) | 10 (10, 12) | 12 (10, 12) | 12 (10, 12) | 12 (10, 12) | 12 (10, 12) | 11 (10, 12) | 12 (11, 14) | 13.5 (11, 14) | |
| FiO2, % | Remifentanil | 60 (50, 70) | 60 (50, 70) | 60 (50, 70) | 60 (50, 70) | 60 (50, 70) | 60 (50, 70) | 50 (50, 60) | 50 (50, 60) | 60 (45, 60) | 60 (50, 70) |
| Dexmedetomidine | 60 (50, 70) | 50 (50, 70) | 50 (50, 70) | 50 (50, 70) | 50 (50, 77.5) | 50 (50, 75) | 50 (50, 70) | 50 (50, 50) | 50 (42.5, 50) | 50 (50, 50) | |
| Tidal volume, mL/kg, PBW | Remifentanil | 8 (7, 10) | 8 (7, 10) | 9 (7, 10) | 9 (7, 10) | 9 (7, 10) | 8 (7, 10) | 9 (7, 9) | 8 (7, 10) | 9 (8, 9) | 9 (8, 10) |
| Dexmedetomidine | 8 (7, 11) | 8 (7, 11) | 9 (7, 11) | 9 (8, 11) | 9 (8, 10) | 8 (8, 10) | 9 (8, 11) | 9 (8, 12) | 9 (8, 12) | 9 (8, 10) | |
| Vital signs | |||||||||||
| HR, beats/min | Remifentanil | 101±19 | 100±20 | 98±20 | 98±20 | 96±19 | 97±21 | 93±16 | 100±23 | 88±15 | 89±18 |
| Dexmedetomidine | 97±17 | 92±20 | 91±17 | 88±18 | 83±15 | 81±14 | 86±20 | 84±16 | 80±19 | 77±20 | |
| SBP, mmHg | Remifentanil | 135±23 | 132±22 | 128±20 | 132±20 | 131±23 | 130±17 | 128±19 | 128±20 | 128±16 | 124±11 |
| Dexmedetomidine | 131±23 | 126±22 | 123±19 | 114±18 | 123±15 | 124±15 | 121±13 | 131±18 | 127±15 | 126±25 | |
| DBP, mmHg | Remifentanil | 64±12 | 63±12 | 59±11 | 61±10 | 63±12 | 63±14 | 64±8 | 61±11 | 64±9 | 68±7 |
| Dexmedetomidine | 64±15 | 61±12 | 61±13 | 59±12 | 60±12 | 61±9 | 59±9 | 63±11 | 61±14 | 66±12 | |
| MAP, mmHg | Remifentanil | 88±13 | 86±12 | 82±11 | 84±10 | 86±12 | 85±12 | 85±9 | 61±11 | 85±8 | 87±6 |
| Dexmedetomidine | 86±16 | 83±12 | 81±13 | 78±12 | 81±10 | 82±9 | 80±9 | 63±11 | 83±12 | 86±14 | |
| SPO2, % | Remifentanil | 97±3 | 98±2 | 98±2 | 98±2 | 98±2 | 99±1 | 99±1 | 99±1 | 99±1 | 99±1 |
| Dexmedetomidine | 97±3 | 98±3 | 98±2 | 99±2 | 99±2 | 99±1 | 99±1 | 99±1 | 99±1 | 99±1 | |
| RR, breaths/min | Remifentanil | 23±6 | 22±5 | 20±6 | 20±6 | 20±5 | 21±5 | 22±7 | 20±6 | 21±6 | 22±6 |
| Dexmedetomidine | 24±7 | 23±6 | 22±5 | 21±6 | 21±5 | 22±6 | 22±5 | 21±5 | 22±3 | 23±5 | |
| NIS | Remifentanil | 2 (1, 2) | 1 (1, 2) | 1 (1, 2) | 1 (1, 2) | 1 (1, 2) | 1 (1, 1.75) | 1 (1, 1) | 1 (1, 1) | 1 (1, 1.5) | 1 (1, 1) |
| Dexmedetomidine | 2 (1, 3) | 2 (1, 2) | 2 (1, 2) | 1 (1, 2) | 1 (1, 2) | 1 (1, 2) | 1 (1, 1.75) | 1 (1, 2) | 1 (1, 1) | 1 (1, 1) | |
| RASS score | Remifentanil | 1 (0, 1) | 0 (0, 0) | 0 (0, 0) | 0 (0, 0) | 0 (0, 0) | 0 (0, 0) | 0 (0, 0) | 0 (0, 0) | 0 (-0.5, 0) | 0 (0, 0) |
| Dexmedetomidine | 1 (0, 2) | 0 (0, 1) | 0 (0, 0) | 0 (0, 0) | 0 (0, 0) | 0 (0, 0) | 0 (0, 0) | 0 (0, 0) | 0 (0, 0) | 0 (0, 0) | |
| Dose of medication | |||||||||||
| µg/kg/min | Remifentanil | 0.06±0.02 | 0.06±0.02 | 0.06±0.02 | 0.06±0.02 | 0.05±0.02 | 0.06±0.02 | 0.06±0.02 | 0.06±0.03 | 0.06±0.03 | 0.05±0.03 |
| µg/kg/h | Dexmedetomidine | 0.51±0.15 | 0.54±0.17 | 0.57±0.19 | 0.57±0.22 | 0.54±0.19 | 0.54±0.18 | 0.52±0.18 | 0.54±0.18 | 0.48±0.15 | 0.53±0.12 |
| Number of subjects | Remifentanil | 52 | 51 | 48 | 44 | 33 | 24 | 19 | 13 | 9 | 7 |
| Dexmedetomidine | 38 | 37 | 35 | 27 | 22 | 14 | 12 | 8 | 4 | 2 |
Continuous data are presented as the mean (SD) or median (IQR). Categorical data are presented as counts (%). MV, mechanical ventilation; PBW, predicted body weight; HR, heart rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean artery pressure; RR, respiratory rate; NIS, NIV intolerance score; RASS, Richmond Agitation and Sedation Scale.